Barclays raised the firm’s price target on Ligand (LGND) to $160 from $150 and keeps an Overweight rating on the shares. The company’s above-consensus 2025 guidance includes 30% year-over-year royalty revenue 9% adjusted earnings growth at the midpoint, the analyst tells investors in a research note. The firm views Ligand’s five-year updated outlook as compelling.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.